Table 1.
Patient characteristics at baseline
| Characteristic | All patients (n = 444) |
|---|---|
| Age, years | 56.4 ± 12.7 |
| Sex, female | 373 (84.0 %) |
| RA duration (years) | 8.1 ± 8.5 |
| Serum CRP (mg/l) | 27.6 ± 27.9 |
| Tender joint count | 6 (3–11) |
| Swollen joint count | 6 (3–10) |
| DAS28CRP3 score | 4.6 ± 1.0 |
| Disease activity | |
| Mild (2.6 < DAS28 ≤ 3.2) | 31 (7.0 %) |
| Moderate (3.2 < DAS28 ≤ 5.1) | 282 (63.5 %) |
| Severe (DAS28 > 5.1) | 131 (29.5 %) |
| Anti-TNF therapy | |
| Etarnercept | 172 (38.7 %) |
| Infliximab | 242 (54.5 %) |
| Adalimumab | 30 (6.8 %) |
| Other medications | |
| Methotrexate | 354 (79.7 %) |
| Prednisolone | 283 (65.1 %)*a |
| Anti-TNF naïve at baseline | 419 (94.4 %) |
| Switching to a new anti-TNF agent at baseline | 18 (4.1 %) |
| Ever smoker | 94 (23.4 %)*b |
| ACPA positive | 330 (88.7 %)*c |
| RF positive | 337 (80.1 %)*d |
Results are shown as mean ± SD, median (IQR) or number (%). *Data for these variables were not available for all patients. Sample sizes were as follows a435, b402, c372, d421. RA rheumatoid arthritis, CRP C-reactive protein, Disease Activity Score in 28 joints DAS28, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor